Blocking Ferroptosis Slows Aging and Extends Healthy Lifespan Across Species

Aging accelerates as cells accumulate damage and lose the ability to manage oxidative stress. Ferroptosis—a form of programmed cell death triggered by iron accumulation and lipid peroxidation—has emerged as a candidate mechanism linking oxidative damage to age-related decline. Yet direct evidence connecting ferroptosis inhibition to improved healthspan in mammals had been limited. This study provides that evidence across multiple experimental systems.

The researchers established three senescence models in primary human foreskin fibroblast (HFF) cells: D-galactose (D-gal)-induced senescence, doxorubicin (DOXO)-induced senescence, and replicative senescence via 30 serial passages. Across all three models, the lipid peroxidation probe C11-BODIPY showed time- and concentration-dependent increases in fluorescence, reactive oxygen species (ROS) measured by DHE staining rose in parallel, GPX4 and FTL protein levels fell, and the pro-ferroptotic protein ACSL4 increased—collectively confirming that ferroptosis intensifies as cells senesce.

To test causality, HFF cells were treated with ferroptosis inducers Erastin (5–10 µM) and RSL3 (0.625–1.25 µM) at sub-lethal doses for five days. Both compounds dose-dependently increased SA-β-galactosidase-positive (senescent) cells, upregulated senescence markers P16 and P21 at both protein and mRNA levels, and elevated expression of multiple SASP factors including IL-1α, IL-1β, IL-6, CXCL-3, CXCL-8, MMP-9, and MMP-12. This confirmed that inducing ferroptosis is sufficient to drive senescence. Conversely, treatment with ferroptosis inhibitors Fer-1 and Lip-1 significantly reduced senescence across all three stress models, decreased SA-β-gal activity, lowered P16/P21 expression, and suppressed SASP gene transcription—demonstrating that blocking ferroptosis can mitigate senescence regardless of the initiating stressor.

Moving to whole-organism models, Fer-1 treatment in C. elegans extended both mean and maximum lifespan and improved healthspan metrics including motility and pharyngeal pumping rates. In mice, two complementary in vivo models were used: a D-gal-accelerated aging model and a naturally aged cohort. In both, Fer-1 administration improved motor performance on rotarod and open-field tests, preserved histological integrity of key tissues (brain, liver, kidney, muscle), mitigated cognitive decline in Morris water maze and novel object recognition tasks, and upregulated GPX4 expression in brain and peripheral tissues. Importantly, long-term Fer-1 treatment exceeding six months produced no adverse changes in body weight, liver enzymes, or histopathology, and actually rejuvenated hematological parameters toward more youthful profiles.

These findings collectively establish ferroptosis as a mechanistically central driver—not merely a bystander—of cellular senescence and systemic aging, and highlight GPX4 upregulation as a key effector of Fer-1's benefits. The results position ferroptosis inhibition as a promising, translatable strategy to extend healthy lifespan.